Member access

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  ABLYNX    ABLX   BE0003877942

ABLYNX

 (ABLX)

134
Delayed Quote. Delayed Euronext Bruxelles - 05/17 11:35:01 am
6.55 EUR   -1.95%
3d ago ABLYNX: Announces q1 2013 business update
05/10ABLYNX NV: quaterly earnings release
05/08 ABLYNX: Publication in accordance with article 14 of the belgian law of 2 ..
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 

ABLYNX (D) : PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

04/27/2012| 12:05pm US/Eastern
Recommend:
0

REGULATED INFORMATION

GHENT, Belgium, 27 April 2012 - Ablynx [Euronext Brussels: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from vzw VIB.

The above shareholder now owns less than 3% in Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, section Investors:
http://www.ablynx.com/en/investors/shareholder-information/shareholder-structure/.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t:   +44 207 920 2330
e:  ablynx@mcomgroup.com:
mailto:ablynx@mcomgroup.com


Complete version of the press release:
http://hugin.info/137912/R/1607016/509633.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE

HUG#1607016
Recommend :
0
Partner Area
React to this article
 
Latest news on ABLYNX
3d ago ABLYNX: Announces q1 2013 business update
05/10ABLYNX NV: quaterly earnings release
05/08 ABLYNX: Publication in accordance with article 14 of the belgian law of 2 may 2..
05/07 ABLYNX: STARTS PRE-CLINICAL DEVELOPMENT OF ALX-0962, AN ANTI-IgE NANOBODY, TO T..
04/22 ABLYNX: Announces warrant exercise
04/17 ABLYNX: Publication in accordance with article 14 of the belgian law of 2 may 2..
03/26 ABLYNX: Notice of ablynx's annual and extraordinary general meeting of sharehol..
03/08 ABLYNX: Publication in accordance with articles 14 and 15 of the belgian law of..
02/28 ABLYNX (D): Ablynx successfully raises €31.5 million, in total €45 million plac..
02/28 ABLYNX (D): Successfully raises ?31.5 million, in total ?45 million placed
Advertisement
Chart
Duration : Period :
ABLYNX Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Income Statement Evolution
ABLYNX : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.